ArticleScience (New York, N.Y.)2020
Genetics of schizophrenia in the South African Xhosa.
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 5 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Genome-wide association study in 404,302 individuals identifies 7 significant loci for reaction time variability.Molecular psychiatry · 2023Pooled it
- Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses.Nature medicine · 2023Pooled it
- A Systematic Review of the Human Accelerated Regions in Schizophrenia and Related Disorders: Where the Evolutionary and Neurodevelopmental Hypotheses Converge.International journal of molecular sciences · 2023Pooled it
- Systematic Review and Meta-Analysis of Mass Spectrometry Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Schizophrenia.International journal of molecular sciences · 2022Pooled it
- Genome-wide association study followed by trans-ancestry meta-analysis identify 17 new risk loci for schizophrenia.BMC medicine · 2021Pooled it
- Neuropsychiatry genetics in Africa.Nature communications · 2026Review
- Thalamic reticular nucleus in the pathophysiology of schizophrenia.Neural regeneration research · 2026Article
- The Molecular Machinery of Synaptic Plasticity and Its Potential Role in the Aetiology of Schizophrenia.Molecular neurobiology · 2026Review
- Article
- Loss of function of the chromatin remodeling geneProceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Key Regulator of Dendritic Morphology in Supragranular Neocortex Impacts Mismatch Negativity.bioRxiv : the preprint server for biology · 2026Article
- Exploring the relationships between Early Childhood Adversity, Social Cognition, and Aggression in a South African Study of People Living with Schizophrenia.Schizophrenia research. Cognition · 2025Review
- Neuroanatomical characterization of the cell adhesion molecule IgSF9b reveals localization to inhibitory and excitatory synapses in the mouse limbic system.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Review
- Lessons learned from the translation of the Internalised Stigma of Mental Illness (ISMI) scale into isiXhosa for use with South African Xhosa people with schizophrenia.Transcultural psychiatry · 2025Article
- Identification and characterization of human KALRN mRNA and Kalirin protein isoforms.Cerebral cortex (New York, N.Y. : 1991) · 2024Article
- Disability benefits protect against lost income for South Africans living with Schizophrenia.Social psychiatry and psychiatric epidemiology · 2024Article
- A preliminary metabolomics study of the database for biological samples of schizophrenia among Chinese ethnic minorities.BMC psychiatry · 2024Article
- Differential Effects of Neonatal Ventral Hippocampus Lesion on Behavior and Corticolimbic Plasticity in Wistar-Kyoto and Spontaneously Hypertensive Rats.Neurochemical research · 2024Article
- Novel α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) potentiator LT-102: A promising therapeutic agent for treating cognitive impairment associated with schizophrenia.CNS neuroscience & therapeutics · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors at 8 institutions in 2 countries.
Funding
Abstract
Africa, the ancestral home of all modern humans, is the most informative continent for understanding the human genome and its contribution to complex disease. To better understand the genetics of schizophrenia, we studied the illness in the Xhosa population of South Africa, recruiting 909 cases and 917 age-, gender-, and residence-matched controls. Individuals with schizophrenia were significantly more likely than controls to harbor private, severely damaging mutations in genes that are critical to synaptic function, including neural circuitry mediated by the neurotransmitters glutamine, γ-aminobutyric acid, and dopamine. Schizophrenia is genetically highly heterogeneous, involving severe ultrarare mutations in genes that are critical to synaptic plasticity. The depth of genetic variation in Africa revealed this relationship with a moderate sample size and informed our understanding of the genetics of schizophrenia worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.